SNY logo

SNY
Sanofi-Aventis

5,835
Mkt Cap
$107.23B
Volume
1.58M
52W High
$53.03
52W Low
$42.33
PE Ratio
18.63
SNY Fundamentals
Price
$45.00
Prev Close
$44.67
Open
$44.78
50D MA
$45.51
Beta
0.31
Avg. Volume
2.73M
EPS (Annual)
$2.41
P/B
1.29
Rev/Employee
$643,658.13
$134,040.08
Loading...
Loading...
News
all
press releases
Teva Stock Up More Than 100% in a Year: Time to Buy, Hold or Sell?
Teva's branded drug growth, biosimilar launches and improving margins are strengthening its long-term outlook despite generics pressure.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Ralph Baric And UNC's Biodefense Contract Racket Exposed
Ralph Baric And UNC's Biodefense Contract Racket Exposed Authored by Paul D. Thacker via The DisInformation Chronicle, DLA Piper wants to get you, I was told, from a source in DC over the weekend...
Zero Hedge·7d ago
News Placeholder
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Zacks·13d ago
News Placeholder
NVAX Q1 Earnings Beat, Stock Jumps 16% on Matrix-M Deal Momentum
Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.
Zacks·14d ago
News Placeholder
NVAX Stock Eyes Breakout Week: Novavax Claims Patients Were ‘Twice As Likely’ To Pick Its COVID Shot Over Moderna Again
The company spotlighted new data showing that its COVID vaccine, Nuvaxovid, produced “statistically fewer side effects” than Moderna’s mNEXSPIKE vaccine.
Stocktwits·15d ago
News Placeholder
Sanofi $SNY Shares Sold by UBS Group AG
UBS Group AG reduced its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 3.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and...
MarketBeat·15d ago
News Placeholder
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
Zacks·16d ago
News Placeholder
Sanofi (NASDAQ:SNY) Sets New 1-Year Low - Should You Sell?
Sanofi (NASDAQ:SNY) Sets New 12-Month Low - Time to Sell...
MarketBeat·16d ago
News Placeholder
Sanofi (NASDAQ:SNY) Shares Gap Down Following Analyst Downgrade
Sanofi (NASDAQ:SNY) Shares Gap Down Following Analyst Downgrade...
MarketBeat·17d ago
News Placeholder
M&T Bank Corp Sells 402,012 Shares of Sanofi $SNY
M&T Bank Corp trimmed its stake in Sanofi (NASDAQ:SNY - Free Report) by 97.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,531 shares of the company's stock after selling 402,012 shares during the period. M&T Bank Corp's holdi...
MarketBeat·18d ago
<
1
2
...
>

Latest SNY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.